187 related articles for article (PubMed ID: 33221343)
1. Tumor regression grading after neoadjuvant treatment of esophageal and gastroesophageal junction adenocarcinoma: results of an international Delphi consensus survey.
Saliba G; Detlefsen S; Carneiro F; Conner J; Dorer R; Fléjou JF; Hahn H; Kamaradova K; Mastracci L; Meijer SL; Sabo E; Sheahan K; Riddell R; Wang N; Yantiss RK; Lundell L; Low D; Vieth M; Klevebro F
Hum Pathol; 2021 Feb; 108():60-67. PubMed ID: 33221343
[TBL] [Abstract][Full Text] [Related]
2. Histopathologic tumor regression grading in patients with gastric carcinoma submitted to neoadjuvant treatment: results of a Delphi survey.
Tsekrekos A; Detlefsen S; Riddell R; Conner J; Mastracci L; Sheahan K; Shetye J; Lundell L; Vieth M
Hum Pathol; 2019 Feb; 84():26-34. PubMed ID: 30217622
[TBL] [Abstract][Full Text] [Related]
3. Relevant issues in tumor regression grading of histopathological response to neoadjuvant treatment in adenocarcinomas of the esophagus and gastroesophageal junction.
Klevebro F; Tsekrekos A; Low D; Lundell L; Vieth M; Detlefsen S
Dis Esophagus; 2020 Jun; 33(6):. PubMed ID: 32141500
[TBL] [Abstract][Full Text] [Related]
4. Interobserver agreement of a gastric adenocarcinoma tumor regression grading system that incorporates assessment of lymph nodes.
Tsekrekos A; Vieth M; Ndegwa N; Bateman A; Flejou JF; Grabsch HI; Mastracci L; Meijer SL; Saragoni L; Sheahan K; Shetye J; Yantiss R; Lundell L; Detlefsen S
Hum Pathol; 2021 Oct; 116():94-101. PubMed ID: 34284051
[TBL] [Abstract][Full Text] [Related]
5. Classification of pathologic response to neoadjuvant therapy in esophageal and junctional cancer: assessment of existing measures and proposal of a novel 3-point standard.
Donohoe CL; O'Farrell NJ; Grant T; King S; Clarke L; Muldoon C; Reynolds JV
Ann Surg; 2013 Nov; 258(5):784-92; discussion 792. PubMed ID: 24045450
[TBL] [Abstract][Full Text] [Related]
6. Impact of response evaluation for resectable esophageal adenocarcinoma - a retrospective cohort study.
Bachmann R; Bachmann J; Hungbauer A; Schmehl J; Sitzmann G; Königsrainer A; Ladurner R
Int J Surg; 2014 Oct; 12(10):1025-30. PubMed ID: 25192805
[TBL] [Abstract][Full Text] [Related]
7. Clinical assessment of tumor regression grade systems in gastroesophageal adenocarcinoma following neoadjuvant chemotherapy.
Lütken C; Sheikh K; Willemoe GL; Achiam MP; Hasselby JP
Pathol Res Pract; 2021 Aug; 224():153538. PubMed ID: 34243107
[TBL] [Abstract][Full Text] [Related]
8. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
Zhu Y; Sun Y; Hu S; Jiang Y; Yue J; Xue X; Yang L; Xue L
BMC Gastroenterol; 2017 Mar; 17(1):41. PubMed ID: 28292272
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of tumor regression grade following the administration of neoadjuvant chemotherapy as treatment for gastric/gastroesophageal adenocarcinoma: A meta-analysis of 14 published studies.
Hayashi M; Fujita T; Matsushita H
Eur J Surg Oncol; 2021 Aug; 47(8):1996-2003. PubMed ID: 33353828
[TBL] [Abstract][Full Text] [Related]
10. Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy: comparison of 2 commonly used scoring approaches.
Karamitopoulou E; Thies S; Zlobec I; Ott K; Feith M; Slotta-Huspenina J; Lordick F; Becker K; Langer R
Am J Surg Pathol; 2014 Nov; 38(11):1551-6. PubMed ID: 25140894
[TBL] [Abstract][Full Text] [Related]
11. Predictors of Disease Recurrence and Survival in Esophageal Adenocarcinomas With Complete Response to Neoadjuvant Therapy.
Agoston AT; Zheng Y; Bueno R; Lauwers GY; Odze RD; Srivastava A
Am J Surg Pathol; 2015 Aug; 39(8):1085-92. PubMed ID: 26076061
[TBL] [Abstract][Full Text] [Related]
12. Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa.
Shapiro J; ten Kate FJ; van Hagen P; Biermann K; Wijnhoven BP; van Lanschot JJ
Ann Surg; 2013 Nov; 258(5):678-88; discussion 688-9. PubMed ID: 24096766
[TBL] [Abstract][Full Text] [Related]
13. The effect of perioperative chemotherapy for patients with an adenocarcinoma of the gastroesophageal junction: A propensity score matched analysis.
Parry K; van Rossum PS; Haj Mohammad N; Ruurda JP; van Hillegersberg R
Eur J Surg Oncol; 2017 Jan; 43(1):226-233. PubMed ID: 27424786
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of Tumor Regression Grade Based on Ryan Score in Squamous Cell Carcinoma and Adenocarcinoma of Esophagus.
Takeda FR; Tustumi F; de Almeida Obregon C; Yogolare GG; Navarro YP; Segatelli V; Sallum RAA; Junior UR; Cecconello I
Ann Surg Oncol; 2020 Apr; 27(4):1241-1247. PubMed ID: 31664618
[TBL] [Abstract][Full Text] [Related]
15. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.
Schneider PM; Baldus SE; Metzger R; Kocher M; Bongartz R; Bollschweiler E; Schaefer H; Thiele J; Dienes HP; Mueller RP; Hoelscher AH
Ann Surg; 2005 Nov; 242(5):684-92. PubMed ID: 16244542
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of visual residual tumour cells (VRTC) for patients with esophageal squamous cell carcinomas after neoadjuvant therapy followed by surgery.
Wang X; Wang H; Wang H; Huang J; Wang X; Jiang Z; Tan L; Jiang D; Hou Y
BMC Cancer; 2021 Feb; 21(1):111. PubMed ID: 33535987
[TBL] [Abstract][Full Text] [Related]
17. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome.
Wu TT; Chirieac LR; Abraham SC; Krasinskas AM; Wang H; Rashid A; Correa AM; Hofstetter WL; Ajani JA; Swisher SG
Am J Surg Pathol; 2007 Jan; 31(1):58-64. PubMed ID: 17197919
[TBL] [Abstract][Full Text] [Related]
18. Tumor regression grade combined with post-therapy lymph node status: A novel independent prognostic factor for patients treated with neoadjuvant therapy followed by surgery in locally advanced gastroesophageal junction and gastric carcinoma.
Yin H; Yao Q; Xie Y; Niu D; Jiang W; Cao H; Feng X; Li Y; Li Y; Zhang X; Shen L; Chen Y
Cancer Med; 2023 Oct; 12(19):19633-19643. PubMed ID: 37749981
[TBL] [Abstract][Full Text] [Related]
19. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
[TBL] [Abstract][Full Text] [Related]
20. Metabolic tumor constitution is superior to tumor regression grading for evaluating response to neoadjuvant therapy of esophageal adenocarcinoma patients.
Buck A; Prade VM; Kunzke T; Feuchtinger A; Kröll D; Feith M; Dislich B; Balluff B; Langer R; Walch A
J Pathol; 2022 Feb; 256(2):202-213. PubMed ID: 34719782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
